CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 4 enrolled
Drug / intervention
Mifepristonedrug
Likely dose
Mifepristone 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01371565
NCT01371565Phase 3Completed
CompareCT.gov

Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome

Corcept Therapeutics·interventional·Posted Jun 13, 2011·Updated Mar 18, 2014

In Brief

A Phase 3 clinical trial evaluating Mifepristone for Cushing's Disease and Cushing's Syndrome. Completed, enrolled 4 participants across 5 sites.

Detailed Summary

This is a compassionate use study. In addition to providing compassionate use access to mifepristone, objectives of the study will be to evaluate the safety and utility of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome when given on a compassionate use basis. The study will only enroll subjects whose physicians have determined that medical treatment is needed to control the symptoms or signs of hypercortisolemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCushing's Disease, Cushing's Syndrome
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 13, 2011
Enrollment StartNov 1, 2010
Primary CompletionJun 1, 2012
Study CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 15.1 years ago

Interventions

Mifepristonedrug

mifepristone at doses from 300mg/day up to 1200mg/day